APA (7th ed.) Citation

P, B., SR, M., MJ, C., MJ, G., AM, B., SL, M., . . . KK, L. (2015). TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. International journal of oncology, 46(2), 607. https://doi.org/10.3892/ijo.2014.2747

Chicago Style (17th ed.) Citation

P, Brachova, et al. "TP53 Oncomorphic Mutations Predict Resistance to Platinum‑ and Taxane‑based Standard Chemotherapy in Patients Diagnosed with Advanced Serous Ovarian Carcinoma." International Journal of Oncology 46, no. 2 (2015): 607. https://doi.org/10.3892/ijo.2014.2747.

MLA (9th ed.) Citation

P, Brachova, et al. "TP53 Oncomorphic Mutations Predict Resistance to Platinum‑ and Taxane‑based Standard Chemotherapy in Patients Diagnosed with Advanced Serous Ovarian Carcinoma." International Journal of Oncology, vol. 46, no. 2, 2015, p. 607, https://doi.org/10.3892/ijo.2014.2747.